Skip to main content

Table 3 HRs for comparison of time to worsening of EORTC QLQ-C30 scale scores by depth of response and MRD status for pooled treatment arms

From: Health-related quality of life in patients with newly diagnosed multiple myeloma ineligible for stem cell transplantation: results from the randomized phase III ALCYONE trial

EORTC QLQ-C30 scales

Clinical response

MRD vs MRD+

 

(s)CR vs VGPR/PR

SD vs VGPR/PR

 

HR (95% CI)

p value

HR (95% CI)

p value

HR (95% CI)

p value

GHS

0.72 (0.54–0.96)

0.025

1.75 (1.16–2.66)

0.008

0.70 (0.50–0.99)

0.042

Physical functioning

0.88 (0.66–1.17)

0.365

1.60 (0.05–2.45)

0.031

0.79 (0.57–1.10)

0.168

Role functioning

0.93 (0.72–1.20)

0.578

1.55 (1.05–2.27)

0.027

0.84 (0.62–1.12)

0.235

Emotional functioning

0.79 (0.57–1.07)

0.120

1.87 (1.21–2.88)

0.005

0.93 (0.66–1.31)

0.680

Cognitive functioning

0.81 (0.64–1.02)

0.075

1.28 (0.88–1.85)

0.200

1.02 (0.78–1.32)

0.910

Social functioning

0.87 (0.67–1.13)

0.290

1.50 (1.01–2.23)

0.044

0.89 (0.66–1.21)

0.453

Pain

0.72 (0.56–0.94)

0.017

1.22 (0.81–1.86)

0.340

0.60 (0.43–0.83)

0.002

Fatigue

1.01 (0.88–1.29)

0.950

1.44 (0.99–2.10)

0.060

0.98 (0.74–1.29)

0.023

Nausea/vomiting

1.05 (0.80–1.39)

0.733

1.38 (0.88–2.16)

0.158

0.92 (0.67–1.27)

0.610

Dyspnea

0.64 (0.48–0.84)

0.002

1.42 (0.94–2.15)

0.096

0.71 (0.51–0.98)

0.037

Insomnia

0.80 (0.62–1.04)

0.099

1.26 (0.84–1.90)

0.265

0.83 (0.61–1.12)

0.215

Appetite loss

1.05 (0.80–1.39)

0.716

1.67 (1.10–2.55)

0.017

0.96 (0.71–1.31)

0.596

Constipation

0.80 (0.61–1.06)

1.127

1.30 (0.84–2.02)

0.233

0.92 (0.67–1.26)

0.596

Diarrhea

1.03 (0.77–1.38)

0.832

1.39 (0.87–2.24)

0.172

0.89 (0.63–1.24)

0.475

  1. PR partial response; (s)CR (stringent) complete response; SD stable disease; VGPR very good partial response
  2. Worsening of EORTC QLQ-C30 GHS defined as a ≥ 10-point decrease and worsening of EORTC QLQ-C30 pain and fatigue defined as a ≥ 10-point increase